文献速递主动脉疾病

术者改良开窗支架急诊修复近肾及胸腹主动脉瘤

Endovascular repair of acute juxtarenal and thoracoabdominal aortic aneurysms with surgeon-modified fenestrated endografts.
PubMed 文献 · J Vasc Surg · 2019-12-25

单中心回顾性研究纳入54例急性复杂主动脉瘤患者,采用术者改良开窗支架行腔内修复,30天/院内死亡率为16.7%,近半数队列死亡率为3.7%,12及24个月估计生存率分别为73.2%和87.9%无再干预率。

要点

  • 急性复杂主动脉瘤行术者改良开窗支架修复,近半数队列30天死亡率降至3.7%。
  • 破裂患者30天死亡率为50%,症状性患者为7.4%。
  • 12个月和24个月无再干预率分别为87.9%和81.6%。

核心结论

  • 术者改良开窗支架为急性复杂主动脉瘤提供定制化解决方案,中期生存和耐久性良好。

主要发现

  • 54例中男性37例,中位年龄73岁(范围50-85岁),动脉瘤直径76 mm(IQR 58-90 mm)。
  • 50例为急性胸腹主动脉瘤(40例症状性,10例破裂;19例I-III型,31例IV型),4例为肾下EVAR后症状性IA型内漏。
  • 187根目标血管中9根术中或30天内闭塞,30天/院内死亡9例(16.7%),症状性7.4%,破裂50%。
  • 30天/院内死亡率从最初27例的29.6%(8例)降至最近27例的3.7%(1例)(P = .0243)。
  • 脊髓缺血1例(1.9%)且30天内死亡,存活者无需永久肾透析,12和24个月估计生存率73.2%(SE 6.2%)。

临床怎么用

  • 高容量专科主动脉中心可开展术者改良开窗支架修复急性复杂主动脉瘤,需具备相应知识和技能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to report the short- and medium-term outcome of surgeon-modified fenestrated endovascular aneurysm repair (SM-FEVAR) for acute complex aortic aneurysms. METHODS: Interrogation of a prospectively maintained database identified consecutive patients who underwent SM-FEVAR for acute complex aortic aneurysms (including mycotic aneurysms treated with rifampicin-soaked endografts) in a single institution between October 2009 and November 2018. RESULTS: A total of 54 patients (37 men; median age, 73 years [range, 50-85 years]; aneurysm diameter, 76 mm [interquartile range, 58-90 mm]) with acute thoracoabdominal aortic aneurysms (n = 50; 40 symptomatic, 10 ruptured; 19 extent I-III, 31 extent IV) or symptomatic type IA endoleaks after infrarenal endovascular aneurysm repair (n = 4) underwent SM-FEVAR. Seven of the patients had adjunct chimney and periscope stent grafts or surgical bypasses. A total of 187 vessels (mean, 3.4 [range, 1-5] per patient) were targeted for preservation; nine occluded intraoperatively or within 30 days. The 30-day/in-hospital mortality was 16.7% (n = 9; symptomatic, 7.4%; rupture, 50%) and fell significantly from 29.6% (n = 8) in the first 27 patients to 3.7% (n = 1) in the most recent 27 patients (P = .0243). Spinal cord ischemia occurred in one patient (1.9%) who died within 30 days. No survivors required permanent renal dialysis. Estimated survival at 12 and 24 months was 73.2% (standard error [SE], 6.2%). Eight patients underwent 12 late aorta- or graft-related reinterventions. Estimated freedom from reintervention at 12 months and 24 months was 87.9% (SE, 5.2%) and 81.6% (SE, 6.4%), respectively. CONCLUSIONS: In patients with acute complex aneurysms, SM-FEVAR provides a customized solution that is associated with good medium-term survival and durability. The knowledge and skills to perform safe SM-FEVAR should be within the capabilities of high-volume specialist aortic centers.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Juszczak MT, Vezzosi M, Khan M, et al. Endovascular repair of acute juxtarenal and thoracoabdominal aortic aneurysms with surgeon-modified fenestrated endografts. J Vasc Surg. 2019. PMID: 31882311. doi:10.1016/j.jvs.2019.10.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。